Inhibition of renin-angiotensin-aldosterone system in heart failure, or from CONSENSUS to PARADIGM-HF
Authors:
Jiří Vítovec 1; Jindřich Špinar 2; Lenka Špinarová 1
Authors‘ workplace:
I. interní kardio-angiologická klinika LF MU a FN u sv. Anny Brno, přednostka prof. MUDr. Lenka Špinarová, CSc., FESC
1; Interní kardiologická klinika LF MU a FN Brno, pracoviště Bohunice, přednosta prof. MUDr. Jindřich Špinar, CSc., FESC
2
Published in:
Vnitř Lék 2015; 61(5): 470-474
Category:
Reviews
Overview
An historical survey is presented of mortality trials on angiotensin-aldosteron system inhibition in patients with chronic heart failure. From the CONSENSUS trial up to the PARADIGM-HF trial, ACE inhibitors/angiotensin II receptor antagonists (AT1-blockers, ARBs, sartans), along with mineralocorticoid receptor blockers, have been the gold standard of treatment. Both direct renin blocker aliskiren and dual blocker enalapril + neprilysin proved ineffective; on the other hand, the new dual inhibitor valsartan + neprilysin LCZ 696 is a new and promising therapeutic agent for future treatment of chronic heart failure.
Key words:
ACE inhibitors – aliskiren – angiotensin receptor blockers – chronic heart failure – LCZ 696 – mineralocorticoid receptor antagonists – omapatrilat
Sources
1. McMurray JJ. CONSENSUS to EMPHASIS: the overwhelming evidence which makes blockade of the renin-angiotensin-aldosterone system the cornerstone of therapy for systolic heart failure. Eur J Heart Failure 2011; 13(9): 929–936.
2. CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987; 316(23): 1429–1435.
3. The SOLVD investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325(5): 293–302.
4. Cohn JN, Johnson G, Zeische S et al. A comparsion of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991; 325(5): 303–310.
5. The SOLVD investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992; 327(10): 685–691. Erratum in N Engl J Med 1992; 327(24): 1768.
6. The NETWORK investigators. Clinical outcome with enalapril in symptomatic chronic heart failure: A dose comparsion. Eur Heart J 1998; 19(3): 481–489.
7. Packer M, Poole-Wilson PA, Armstrong PW et al. ATLAS Study Group. The Assessment of Treatment with Lisinopril and Survival. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. Circulation 1999; 100(23): 2312–2318.
8. Willenheimer R, van Veldhuisen DJ, Silke B et al. Effect on Survival and Hospitalization of Initiating Treatment for Chronic Heart Failure With Bisoprolol Followed by Enalapril, as Compared With the Opposite Sequence. Results of the Randomized Cardiac Insufficiency Bisoprolol Study (CIBIS) III. Circulation 2005; 112(16): 2426–2435.
9. Cleland JGF, Tendera M, Adamus J et al. PEP-CHF Investigators. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J 2006; 27(19): 2338–2345.
10. Pitt B, Poole-Wilson PA, Segal R et al. ELITE II Investigators. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial – the Losartan Heart Failure Survival Study ELITE II. Lancet 2000; 355(9215): 1582–1587.
11. Cohn JN, Tognoni GA. Valsartan Heart Failure Trial Investigators, A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. New Engl J Med 2001; 345(23): 1667–1675.
12. Pfeffer MA, Swedberger K, Granger CB et al. CHARM Investigators and Committees. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003; 362(9386): 759–766.
13. Massie BM, Carson PE, McMurray JJV et al. I-PRESERVE Investigators. Irbesartan in Patients with Heart Failure and Preserved Ejection Fraction. N Engl J Med 2008; 359(23): 2456–2467.
14. Konstam MA, Neaton JD, Dickstein K et al. HEAAL Investigators. Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial. Lancet 2009; 374(9704): 1840–1848.
15. Pitt B, Zannad F, Remme WJ et al. Randomized Aldactone Evaluation Study Investigators. The effects of Spirolacton on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999; 341(10): 709–717.
16. Zannad F, McMurray JJ, Krum H et al. EMPHASIS-HF Study Group. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011; 364(1): 11–21.
17. Pitt B, Pfeffer MA, Assmann FA et al. TOPCAT Investigators. Spironolactone for Heart Failure with Preserved Ejection Fraction. N Engl J Med 2014; 370(15): 1383–1392.
18. Gheorghiade M, Böhm M, Greene SJ et al. ASTRONAUT Investigators and Coordinators. Effect of Aliskiren on Postdischarge Mortality and Heart Failure Readmissions Among Patients Hospitalized for Heart Failure. JAMA 2013; 309(11): 1125–1135.
19. Packer M, Califf RM, Konstam MA et al. OVERTURE Study Group. Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE). Circulation 2002; 106(8): 920–926.
20. McMurray JJV, Packer M, Desai AS et al. PARADIGM-HF Investigators and Committees. Angiotensin-Neprilysin Inhibition versus Enalapril in Heart Failure. N Engl J Med 2014; 371(11): 993–1004.
Labels
Diabetology Endocrinology Internal medicineArticle was published in
Internal Medicine
2015 Issue 5
Most read in this issue
- Hyperosmolar hyperglycemic state
- Hemocoagulation – New views on the old cascade
- The role of uric acid and allopurinol therapy in cardiovascular disease
- Hypertension in females